Risk factors for severe respiratory syncytial virus lower respiratory tract infection
about
The use of antibiotics for preventing lower respiratory tract infections in at risk children less than 12 years oldAntibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and underLamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatmentsRespiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysisThe Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab - validation against two external data sources.Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab ProphylaxisA novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.Respiratory syncytial virus infections in infants affected by primary immunodeficiency.Exposure to infections and risk of leukemia in young children.Measles-mumps-rubella vaccination and respiratory syncytial virus-associated hospital contactRespiratory syncytial virus-associated hospitalizations in pre-mature infants in Lima, PeruSafety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.Evaluation of IgG Antibodies Against Respiratory Syncytial Virus (RSV), and Associated Risk Factors for Severe Respiratory Tract Infections in Pre-School Children in North-Central, Nigeria.Sucrose stabilization of Respiratory Syncytial Virus (RSV) during nebulization and experimental infection.Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort.Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).Safely Discharging Infants with Bronchiolitis from an Emergency Department: A Five Step Guide for Pediatricians.A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma.The prevalence and risk factors of allergic and respiratory symptoms in a regional cohort of extremely low birth weight children (<1000 g)Trend of invasive pneumococal disease (IPD) in a South Western, Nigerian hospitalRespiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registriesThe Burden of Severe Respiratory Syncytial Virus Disease Among Children Younger than 1 Year in Central and Eastern Europe.Vaccination against RSV: is maternal vaccination a good alternative to other approaches?Strategic priorities for respiratory syncytial virus (RSV) vaccine development.Increased concentration of iodide in airway secretions is associated with reduced respiratory syncytial virus disease severity.First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).Role of Parental Smoking in Severe Bronchiolitis: A Hospital Based Case-Control Study.Human respiratory syncytial virus memphis 37 causes acute respiratory disease in perinatal lamb lung.Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?A review of cost-effectiveness of palivizumab for respiratory syncytial virus.Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study.Immunization of high-risk paediatric populations: Central European Vaccination Awareness Group recommendations.Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.The Role of Human Milk Immunomodulators in Protecting Against Viral Bronchiolitis and Development of Chronic Wheezing Illness.Epidemiology of laboratory-confirmed respiratory syncytial virus infection in young children in England, 2010-2014: the importance of birth month.Extraribosomal l13a is a specific innate immune factor for antiviral defenseRespiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.
P2860
Q24186293-772B6059-26CF-4F60-BA12-FFD17FDF9A50Q24186994-41234EBF-6A48-4B3F-BC64-FA0A9900C12BQ26830726-C44D33D6-0DB4-4978-82B0-EE1E3053FFD9Q30244591-6CFEDEBB-9789-4CB6-BEC3-DDB374952676Q30968297-4EB40786-9528-4F08-8667-3F11D32423CAQ33628327-57793E85-A064-451D-8B8C-DCD1B43EB83DQ33817471-48199A10-C2C0-4590-AF0F-F95796B02F7AQ33892605-184D9744-E448-41B8-B10E-D19EE34DB808Q33909037-09AFCAA5-E040-43A0-AD43-92025F89E3DEQ34450699-DC7D5FD0-03A9-48CD-AA8F-361DE6F51566Q34496098-7DD6994C-2760-447C-8D99-3745B88B1C54Q34726169-3AB6D9B2-D10E-4BC4-99D2-15D9FA4A4A99Q35075716-40C7B5E9-A949-47FE-9B95-F0ABE48411EFQ35123767-1159DCC4-FD4F-4CAF-A76F-01A312464CDAQ35678345-EB404CB0-2A2D-4F41-B425-1F9529FFC395Q36054311-C23B9936-88F2-4B80-929C-F7D4FF47F84AQ36149998-32AB90C0-B138-4812-9640-41E5FFE06023Q36275397-24CB6F58-93BE-4D80-9216-07DF48A1A498Q36463070-AC1D5851-D864-464A-A20C-A0317F92782EQ36577321-EECBE3E2-2E50-4270-B1C1-9F5C0458ACD7Q36597211-BB24946A-585F-4F8F-AE3D-FD43A7F44A37Q36948273-3819F6F6-79BD-4F6F-AE60-0EDBE2854BD0Q36989863-6E725C05-5FDF-44A5-8A5F-ACA714A20714Q37056532-81BCA470-1DEE-4256-953D-CC4BBAFCB65DQ37514757-C8268756-B1B9-4909-BAB0-CF855A771FE7Q37572640-4DB8C4A1-552A-4D87-98F3-DA7791F3C87FQ37596130-F17682B6-B4E9-4E1C-A522-D03A2346A8B8Q37660572-8EAB3323-F798-4044-A804-61587CEFF51FQ37710217-6D367694-BC56-441F-A919-BB53CDCD01E8Q37715621-EE16913E-9186-4457-A809-E8B1BB7EB909Q38057771-04D999ED-CDB7-4684-9C44-1C1182ED98BBQ38058838-A574B8B8-8429-407A-B524-B135D6AB4CF5Q38115264-AC8F7EA6-7F1E-4724-8D1B-0C52DF8D79C3Q38198120-9BB33271-2C04-4BBB-990F-DA2E44E5C8BAQ38604949-57A53B8E-BE20-4C01-9015-1241AD86BFD8Q38671952-48BE0BBC-F907-4D23-AEF1-C3F31E203E56Q38897076-F4CD91CB-4E14-4F3B-AA32-0F4FE1404210Q38903197-CEB87DD9-0241-40E9-9365-7FCF873B32D6Q38988159-5E95B823-69F0-4504-8F1B-FB6CE8910652Q39025676-B0E5226F-1571-4676-9C69-4221DE36438C
P2860
Risk factors for severe respiratory syncytial virus lower respiratory tract infection
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Risk factors for severe respiratory syncytial virus lower respiratory tract infection
@en
type
label
Risk factors for severe respiratory syncytial virus lower respiratory tract infection
@en
prefLabel
Risk factors for severe respiratory syncytial virus lower respiratory tract infection
@en
P2093
P2860
P1476
Risk factors for severe respiratory syncytial virus lower respiratory tract infection
@en
P2093
Bernhard Resch
Constanze Sommer
Eric A F Simões
P2860
P304
P356
10.2174/1874285801105010144
P577
2011-12-30T00:00:00Z